Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
18 July 2014Website:
http://www.sagerx.comNext earnings report:
07 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 18:19:49 GMTDividend
Analysts recommendations
Institutional Ownership
SAGE Latest News
LOS ANGELES, CA / ACCESSWIRE / July 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / June 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / June 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
LOS ANGELES, CA / ACCESSWIRE / June 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK , May 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") (NASDAQ: SAGE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Sage Therapeutics' (SAGE) financial results for the first quarter of 2024 show a combination of disappointing earnings and strong sales performance, driven by the successful launch of the depression drug Zurzuvae.
Sage Therapeutics, Inc. (NASDAQ:SAGE) held its Q1 2024 Earnings Conference Call on April 25, 2024 at 8:00 AM ET. The call included company representatives Ashley Kaplowitz, Barry Greene, Chris Benecchi, Laura Gault, Kimi Iguchi, and Mike Quirk. Various analysts participated in the call as well. The conference call was for discussing Sage Therapeutics' First Quarter 2024 Financial Results. All participants were in a listen-only mode.
Sage Therapeutics, Inc. (SAGE) reported a quarterly loss of $1.80 per share, which was higher than the expected loss of $1.63 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $2.46 per share reported in the same quarter last year.
Results from a mid-stage trial reveal that Sage's (SAGE) new oral medication did not demonstrate a significant improvement in treating patients with Parkinson's disease when compared to a placebo.
Sage Therapeutics Inc. saw a 17% decrease in its stock value on Wednesday following disappointing results in a clinical trial for its treatment for mild cognitive impairment in Parkinson's disease patients.
- 1(current)
- 2
What type of business is Sage Therapeutics?
Sage Therapeutics, Inc. is a biopharmaceutical company that specializes in the development and commercialization of drugs for the treatment of central nervous system disorders (depression, neuropsychiatric and neurological deviations). Founded in 2010, the company started its operations as Sterogen Biopharma, Inc. in 2011, changed its name to the current one. The corporate headquarters is located in Cambridge, Massachusetts. At the moment, the company has one product that was approved by the FDA in March 2019, and its commercialization began in the second half of that year. ZULRESSO is a drug whose active ingredient is identical to a natural neuroactive steroid. It is used for the treatment of postpartum depression.
What sector is Sage Therapeutics in?
Sage Therapeutics is in the Healthcare sector
What industry is Sage Therapeutics in?
Sage Therapeutics is in the Biotechnology industry
What country is Sage Therapeutics from?
Sage Therapeutics is headquartered in United States
When did Sage Therapeutics go public?
Sage Therapeutics initial public offering (IPO) was on 18 July 2014
What is Sage Therapeutics website?
https://www.sagerx.com
Is Sage Therapeutics in the S&P 500?
No, Sage Therapeutics is not included in the S&P 500 index
Is Sage Therapeutics in the NASDAQ 100?
No, Sage Therapeutics is not included in the NASDAQ 100 index
Is Sage Therapeutics in the Dow Jones?
No, Sage Therapeutics is not included in the Dow Jones index
When does Sage Therapeutics report earnings?
The next expected earnings date for Sage Therapeutics is 07 August 2024